hackint0sh/New-Dataset huggingface dataset:
Researchers will compare neutral, forward and backward head positions to see if there are any difference in number, density and location of occlusal contacts. conditions: Occlusion studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 36 type: ACTUAL name: Digital Interocclusal Record In Different Head Positions measure: Number of Occlusal Contacts measure: Density of Occlusal Contacts measure: Location of Occlusal Contacts sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hacettepe University city: Ankara country: Turkey lat: 39.91987 lon: 32.85427 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-04-17 uploadDate: 2024-03-29T04:39 filename: Prot_SAP_000.pdf size: 212403 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2023-04-17 uploadDate: 2024-03-29T04:39 filename: ICF_001.pdf size: 97067 hasResults: False
nctId: NCT06343441 id: SH9H-2024-T29-2 briefTitle: Accuracy of Two Methods of Making Impressions for Complete-arch Implant Supported Fixed Prosthesis overallStatus: NOT_YET_RECRUITING date: 2024-03-31 date: 2024-12-31 date: 2024-12-31 date: 2024-04-02 date: 2024-04-02 name: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University class: OTHER briefSummary: To compare the accuracy of digital impression and conventional impression for complete-arch implant-supported fixed prosthesis conditions: Edentulous Jaw studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 22 type: ESTIMATED name: intraoral scan name: open tray impression measure: Grade of framework passive fit sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06343428 id: IEO 1519 briefTitle: Definition of a Multiparametric Prognostic and Predictive System of Classification of NET G3 Patients acronym: TAPIOCA overallStatus: RECRUITING date: 2021-07-19 date: 2024-07-19 date: 2026-07-19 date: 2024-04-02 date: 2024-04-02 name: European Institute of Oncology class: OTHER briefSummary: The 2017 World Health Organization (WHO) introduced a new category of high-grade, well-differentiated neuroendocrine neoplasms (NENs) that called neuroendocrine tumors (NETs) G3 in pancreatic NENs classification and, then, in 2019, for all gastro-entero-pancreatic (GEP) tract NENs.
However, in clinical practice, we observed that several clinical, pathological and radiological differences are arising among NET G3 patients, suggesting that a multiparametric definition of NET G3 is needed. conditions: Neuroendocrine Neoplasm studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 40 type: ESTIMATED measure: Immunohistochemical characteristics analysis measure: Review of the functional imaging sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: European Institute of Oncology status: RECRUITING city: Milan zip: 20141 country: Italy name: Francesca Spada, MD role: PRINCIPAL_INVESTIGATOR lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06343415 id: H-23052844 briefTitle: Robot-assisted Training After Traumatic Brain Injury and Disorders of Consciousness overallStatus: RECRUITING date: 2024-04-16 date: 2025-04-30 date: 2025-07-31 date: 2024-04-02 date: 2024-04-17 name: Christina Kruuse class: OTHER briefSummary: The goal of this randomised cross-over feasibility trial is to investigate two intensive robot-assisted training therapies in the early rehabilitation phase after traumatic brain injury and disorders of consciousness. The main questions it aims to answer are:
The investigators will explore and compare safety events, physiological measures and physical activity levels, behavioural measures, and functional disability outcomes. Further, the investigators report intervention and technical parameters in detail. conditions: Traumatic Brain Injury conditions: Disorders of Consciousness studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: AB - BA primaryPurpose: OTHER masking: SINGLE maskingDescription: Assessors are blinded to allocation for the following exploratory clinical outcome scales: "Disability Rating Scale" and "Coma Recovery Scale-Revised".
Data analyses are blinded by coding and blinding the groups (groups A and B) for the statistical analyses. After the analysis, two separate conclusions will be written before lifting the blinding and revealing the results. whoMasked: OUTCOMES_ASSESSOR count: 17 type: ESTIMATED name: GAIT-assisted training name: STEP-assisted training measure: Inclusion Rate measure: Completion Ratio of protocols measure: Exploratory Safety Outcomes measure: Disability Rating Scale (DRS) measure: Coma Recovery Scale-Revised (CRS-R) and level of consciousness measure: Early Functional Abilities (EFA) measure: Functional Independence Measure (FIM) measure: Physical activity intensity measure: Mean arterial pressure (MAP) measure: Heart Rate Variability (HRV) measure: Behavioural Outcome sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of brain and spinal cord injury status: RECRUITING city: Glostrup state: Greater Copenhagen zip: 2600 country: Denmark name: Christina Kruuse, Professor role: CONTACT email: christina.kruuse@regionh.dk name: Vibeke Wagner, MSc role: PRINCIPAL_INVESTIGATOR lat: 55.6666 lon: 12.40377 hasResults: False
nctId: NCT06343402 id: TBBO8520-101 id: ONKORAS-101 type: OTHER domain: TheRas briefTitle: Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer overallStatus: RECRUITING date: 2024-04 date: 2027-08 date: 2028-02 date: 2024-04-02 date: 2024-04-22 name: TheRas, Inc class: INDUSTRY briefSummary: A first in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-8520, a KRAS G12C (ON) inhibitor, single agent and in combination with pembrolizumab in patients with advanced non-small cell lung cancer conditions: Non-small Cell Lung Cancer conditions: Metastatic Non-Small Cell Lung Cancer conditions: NSCLC conditions: KRAS G12C conditions: Metastatic Lung Cancer conditions: Advanced Lung Carcinoma studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: Phase 1a: sequential/parallel, Phase 1b: parallel primaryPurpose: TREATMENT masking: NONE count: 160 type: ESTIMATED name: BBO-8520 name: Pembrolizumab measure: Adverse Events measure: Dose-limiting toxicities (DLTs) measure: To evaluate preliminary antitumor activity of BBO-8520 measure: To evaluate preliminary antitumor activity of BBO-8520 measure: Overall Survival (OS) measure: To characterize the pharmacokinetics (PK) of BBO-8520 measure: To characterize the pharmacokinetics (PK) of BBO-8520 measure: To characterize the pharmacokinetics (PK) of BBO-8520 measure: To characterize the pharmacokinetics (PK) of BBO-8520 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cleveland Clinic status: RECRUITING city: Cleveland state: Ohio zip: 44195 country: United States lat: 41.4995 lon: -81.69541 facility: SCRI Oncology Partners status: RECRUITING city: Nashville state: Tennessee zip: 37203 country: United States lat: 36.16589 lon: -86.78444 facility: NEXT Oncology status: RECRUITING city: Fairfax state: Virginia zip: 22031 country: United States lat: 38.84622 lon: -77.30637 facility: Peter MacCallum Cancer Centre status: RECRUITING city: Melbourne state: Victoria zip: 3051 country: Australia lat: -37.814 lon: 144.96332 hasResults: False
nctId: NCT06343389 id: Soh-Med-24-03-14MS briefTitle: Acute Kidney Injury in Patients With Liver Cirrhosis overallStatus: RECRUITING date: 2024-04 date: 2024-10 date: 2025-04 date: 2024-04-02 date: 2024-04-02 name: Sohag University class: OTHER briefSummary: In our locality, limited studies have discussed AKI in patients with liver cirrhosis and its outcome, therefore we aim to highlight the incidence, patterns, risk factors, and outcomes of acute kidney injury in patients with liver cirrhosis at Sohag University Hospital. conditions: Acute Kidney Injury in Patients With Liver Cirrhosis studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 200 type: ESTIMATED name: serum creatinine measure: Incidence of acute kidney injury in cirrhotic patients in Sohag University Hospital sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sohag University Hospital status: RECRUITING city: Sohag country: Egypt name: Magdy M Amin, professor role: CONTACT lat: 26.55695 lon: 31.69478 hasResults: False
nctId: NCT06343363 id: 318352 briefTitle: Early Discharge After Mitral and Tricuspid Edge-to-edge Repair: an Assessment of Feasibility and Safety acronym: EARLY-Edge overallStatus: RECRUITING date: 2023-05-01 date: 2025-05 date: 2025-12 date: 2024-04-02 date: 2024-04-02 name: Oxford University Hospitals NHS Trust class: OTHER name: Edwards Lifesciences briefSummary: Mitral regurgitation (MR) and tricuspid regurgitation (TR) are common causes of breathlessness, fluid retention and other heart failure symptoms, which lead to reduced quality of life and frequent hospitalisation. These conditions are particularly prevalent in older adults with many of these patients being at high risk for surgical intervention due to frailty and comorbidities, leaving them with few treatment alternatives.
Transcatheter edge-to-edge repair (TEER) procedures have increasingly been used to improve the severity of both MR and TR, offering patients symptomatic relief and reductions in heart failure hospitalisation at low procedural risk. There is considerable geographic variation in protocols to assess these patients prior to the procedure and also in length of hospital stay. The standard of care in the UK, and particularly in Oxford, emphasises fewer investigations before the TEER procedure and shorter length of hospital stay.
This prospective, observational cohort study will examine the safety and feasibility of this practice. conditions: Mitral Regurgitation conditions: Tricuspid Regurgitation conditions: Mitral Repair conditions: Heart Failure studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: Early discharge protocol measure: Proportion of patients discharged 'early' after edge -to-edge repair measure: All - cause rehospitalisation after completion of procedure measure: All cause death after completion of procedure measure: Hospital length of stay measure: Proportion of patients requiring intensive care unit care measure: Safety outcomes a. Major adverse events at the time of the procedure b. Major adverse events (procedure/device related) up to 30 days measure: Symptomatic improvement measure: Heart failure hospitalisation sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: John Radcliffe Hospital status: RECRUITING city: Oxford state: Oxfordshire zip: OX3 9DU country: United Kingdom name: Sam Dawkins, MBBS MRCP BSc DPhil role: CONTACT email: Sam.Dawkins@ouh.nhs.uk lat: 51.75222 lon: -1.25596 hasResults: False
nctId: NCT06343350 id: OPTDR01P briefTitle: OPTDR01 Feasibility for Automated Diabetic Retinopathy Detection overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-10-30 date: 2024-12-30 date: 2024-04-02 date: 2024-04-02 name: Optain Health class: INDUSTRY briefSummary: In the United States, only 62% of the 37 million people with diabetes receive annual screening exams for diabetic retinopathy. One of the goals of the US Department of Health and Human Services Healthy People 2030 campaign is to increase diabetic retinopathy screening rates to 70.3%. Research indicates that low screening rates are associated with a variety of factors, including income levels, race and lack of access to care. Furthermore, because diabetic retinopathy frequently presents asymptomatically, non-adherence to screening results in postponed disease detection and a higher probability of vision loss. Currently, it is estimated that 9 million adults in the US are affected by diabetic retinopathy, and 1.8 million suffer from vision-threatening diabetic retinopathy. Importantly, the rates of vtDR vary greatly by race, with Hispanic individuals at 7.14% and Black individuals at 8.66%, compared to 3.55% in White individuals. Despite these alarming figures, the disease can be managed and vision loss can often be averted with early disease detection, thus highlighting the importance of increasing screening rates.
A clear need exists for a diabetic retinopathy screening tool that can be deployed in primary care settings, addressing the shortage of specialist care and making screening more accessible to underserved populations. OPTDR01 will directly address these issues by providing accessible, high quality screening for diabetic retinopathy. OPTDR01 will automatically detect more than mild diabetic retinopathy (mtmDR) and vision-threatening diabetic retinopathy (vtDR) in diabetic adults who have not previously been diagnosed with mtmDR or vtDR. conditions: Diabetic Retinopathy conditions: Diabetes studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 75 type: ESTIMATED name: OPTDR01 software application measure: Enrollment rate of eligible participants at clinical site sex: ALL minimumAge: 22 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Precision Research Institute city: San Diego state: California zip: 92114 country: United States name: Marie Inocentes role: CONTACT phone: 619-501-0371 phoneExt: 310 email: marie@prisandiego.com lat: 32.71533 lon: -117.15726 hasResults: False
nctId: NCT06343337 id: MSKUDİSCLİNİCALTRİALS_FYİLMAZ. briefTitle: The Effects of Pregnancy on Oral Health overallStatus: COMPLETED date: 2022-05-20 date: 2023-04-01 date: 2023-04-01 date: 2024-04-02 date: 2024-04-02 name: Muğla Sıtkı Koçman University class: OTHER briefSummary: The aim of this study was to evaluate the effects of pregnancy on salivary pH, flow rate, caries experience and periodontal status.
* Is there a difference among first, second and third trimester with respect to caries experience, periodontal status, salivary pH and flow rate? conditions: Pregnancy Related conditions: Dental Caries conditions: Periodontal Diseases conditions: Saliva Altered studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: FACTORIAL primaryPurpose: DIAGNOSTIC masking: SINGLE maskingDescription: The individual who evaluates the salivary pH and flow rate. whoMasked: OUTCOMES_ASSESSOR count: 198 type: ACTUAL name: Evaluation of DMFT index, CPI scores, salivary pH and flow rate in pregnant and non-pregnant woman measure: The effects of pregnancy on caries experience measure: The effects of pregnancy on periodontal status. measure: The effects of pregnancy on salivary pH. measure: The effects of pregnancy on salivary flow rate. sex: FEMALE minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT facility: Fatma Yilmaz city: Mentese state: Mugla zip: 48000 country: Turkey hasResults: False
nctId: NCT06343324 id: 2023/012 briefTitle: Effect of Web-Based Adaptation and Insomnia Severity in Individuals Using Noninvasive Ventilators at Home overallStatus: ENROLLING_BY_INVITATION date: 2024-01-01 date: 2024-02-01 date: 2024-04-01 date: 2024-04-02 date: 2024-04-03 name: KTO Karatay University class: OTHER briefSummary: Home use of the NIV device, which is used to manage respiratory failure, one of the most disturbing symptoms due to COPD, will continue to increase. There is a need for studies evaluating the effectiveness of the use of WEB-based training programs in making patients and their families independent in the use of this device. This study will produce evidence for this effect and contribute to the awareness of healthcare professionals working in this field. The WEB-based training module to be developed aims to increase compliance with NIV in patients using NIV at home for a long time and to manage symptoms such as insomnia that may develop due to NIV. conditions: Noninvasive Ventilation conditions: COPD studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Web-based education measure: Patient Identifiable Characteristics Form measure: S³-NIV Questionnaire measure: insomnia severity index measure: Expected behavioral changes in the individual survey sex: ALL minimumAge: 50 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Health Sciences University Konya Beyhekim Training and Research Hospital city: Konya state: Selçuklu zip: 42060 country: Turkey lat: 37.87135 lon: 32.48464 hasResults: False
nctId: NCT06343311 id: EBUS22CD19AR100 briefTitle: T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) acronym: Starlight-1 overallStatus: NOT_YET_RECRUITING date: 2024-05-15 date: 2026-12-31 date: 2027-12-31 date: 2024-04-02 date: 2024-04-18 name: Estrella Biopharma, Inc. class: INDUSTRY name: Eureka Therapeutics Inc. briefSummary: This is an open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety of an autologous T-cell therapy (EB103) and to determine the Recommended Phase II Dose (RP2D) in adult subjects (≥ 18 years of age) who have relapsed/refractory (R/R) B-cell NHL. The study will include a dose escalation phase followed by an expansion phase. conditions: B-Cell Non-Hodgkin's Lymphoma (NHL) conditions: Lymphoma, Non-Hodgkins conditions: Lymphomas Non-Hodgkin's B-Cell conditions: Non-Hodgkin Lymphoma conditions: Non-Hodgkin's Lymphoma conditions: Large B-Cell Lymphoma conditions: Lymphoma, Non-Hodgkin's, Adult conditions: Lymphoma conditions: Refractory Non-Hodgkin Lymphoma conditions: Relapsed Non-Hodgkin Lymphoma conditions: Lymphoma, Non-Hodgkin conditions: HIV Associated Lymphoma conditions: CNS Lymphoma conditions: High-grade B-cell Lymphoma conditions: Refractory B-Cell Non-Hodgkin Lymphoma studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 21 type: ESTIMATED name: EB103 measure: To assess the Dose Limiting Toxicities of EB103. measure: Incidence rates of Treatment-Emergent Adverse Events of EB103. measure: Incidence rates Treatment-Emergent Laboratory Abnormalities reported for EB103. measure: To determine the Recommended Phase II Dose (RP2D) of EB103. measure: To assess the Overall Response Rate of EB103 in our study subject population. measure: To assess the Disease Control Rate of EB103 in our study subject population. measure: To assess the Duration of Response of EB103 in our study subject population. measure: To assess the Progression-Free Survival rate of EB103 in our study subject population. measure: To assess the Event-Free Survival rate of EB103 in our study subject population. measure: To assess the Overall Survival rate of EB103 in our study subject population. measure: To characterize the pharmacokinetic (PK) profile of EB103 by measuring the peak exposure (Cmax). measure: To characterize the pharmacokinetic (PK) profile of EB103 by measuring the time to reach peak exposure (Tmax). measure: To characterize the pharmacokinetic (PK) profile of EB103 by measuring the partial area under the curve (pAUC). sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06343298 id: ES_MANP_2001 briefTitle: To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2025-07-01 date: 2025-08-01 date: 2024-04-02 date: 2024-04-10 name: E-Star BioTech, LLC class: INDUSTRY name: Mayo Clinic name: PPD briefSummary: This is a Phase 2 dose-titration study designed to evaluate the safety and efficacy of MANP subcutaneous injection compared to placebo in reducing baseline daytime systolic blood pressure (SBP), derived from 24-hour ambulatory blood pressure monitoring (ABPM), in subjects with hypertension who are taking 3 or more antihypertensive medications with different mechanisms of action. conditions: Difficult to Control Hypertension studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 132 type: ESTIMATED name: MANP name: Placebo Matched control measure: Change from baseline in mean daytime SBP derived from 24-hour ABPM at approximately Day 42. measure: Incidence and severity of Adverse events through 4- weeks post end of treatment. measure: Incidence and severity of Serious Adverse Events through 4- weeks post end of treatment. measure: Incidence and severity of Treatment Emergent Adverse Events through 4- weeks post end of treatment. measure: Change in Clinic sitting systolic blood pressure measure: Pharmacokinetics - Cmax measure: Pharmacokinetics - Tmax measure: Anti-drug Antibody measure: Differential Outcomes in African-American Subject versus Non-African American Subjects measure: Metabolic biomarkers - Glucose measure: Metabolic biomarkers - Insulin measure: Metabolic biomarkers - HbA1C measure: Lipid biomarkers - HDL measure: Lipid biomarkers - LDL measure: Lipid biomarkers - TG sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06343285 id: 20231215 briefTitle: Upper Limb Tremor Reduction in Essential Tremor Patients acronym: ULTRE overallStatus: RECRUITING date: 2024-01-01 date: 2024-05 date: 2024-06 date: 2024-04-02 date: 2024-04-03 name: Encora, Inc. class: INDUSTRY briefSummary: This study is designed to demonstrate the safety and tolerability of the Encora Therapeutics Tremor Mitigation Device in subjects with upper limb tremor caused by Essential Tremor. conditions: Essential Tremor studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: Three different arms in a randomized order primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Randomization schedule maintained by non-Clinical personnel whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: Encora Therapeutics Tremor Reduction Device measure: Tolerability measure: Safety measure: Bain & Findley Activity of Daily Living (BF-ADL) #2 measure: BF-ADL #4 measure: BF-ADL #17 measure: BF-ADL #21 measure: Patient Global Impression of Change (PGI-C) measure: Clinician Global Impression of Change (CGI-C) measure: Tremor power as measured by gyroscope measure: The Essential Tremor Rating Scale (TETRAS) #2.4 measure: TETRAS #2.6 measure: TETRAS #2.8 measure: Patient Global Impression of Severity (PGI-S) measure: Clinician Global Impression of Severity (CGI-S) measure: Tremor power as measured by accelerometer sex: ALL minimumAge: 22 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Encora Therapeutics status: RECRUITING city: Cambridge state: Massachusetts zip: 02139 country: United States name: Kristi Winterfeldt, MSHS role: CONTACT phone: 763-248-1210 email: kristi@encoratherapeutics.com name: Taylor Robertson role: CONTACT phone: 7814221105 email: taylor@encoratherapeutics.com name: Kristi Winterfeldt, MSHS role: PRINCIPAL_INVESTIGATOR name: Fatta Nahab, MD role: SUB_INVESTIGATOR lat: 42.3751 lon: -71.10561 hasResults: False